keyword
MENU ▼
Read by QxMD icon Read
search

Non-secretory multiple myeloma

keyword
https://www.readbyqxmd.com/read/27842666/simplified-response-monitoring-criteria-for-multiple-myeloma-in-patients-undergoing-therapy-with-novel-agents-using-computed-tomography
#1
Christoph Schabel, Marius Horger, Sara Kum, Katja Weisel, Jan Fritz, Sorin D Ioanoviciu, Georg Bier
INTRODUCTION: Multiple myeloma is a malignant hematological disorder of the mature B-cell lymphocytes originating in the bone marrow. While therapy monitoring is still mainly based on laboratory biomarkers, the additional use of imaging has been advocated due to inaccuracies of serological biomarkers or in a-secretory myelomas. Non-enhanced CT and MRI have similar sensitivities for lesions in yellow marrow-rich bone marrow cavities with a favourable risk and cost-effectiveness profile of CT...
December 2016: European Journal of Radiology
https://www.readbyqxmd.com/read/27795747/dynamic-analysis-of-immune-and-cancer-cell-interactions-at-single-cell-level-in-microfluidic-droplets
#2
S Sarkar, P Sabhachandani, D Stroopinsky, K Palmer, N Cohen, J Rosenblatt, D Avigan, T Konry
Cell-cell communication mediates immune responses to physiological stimuli at local and systemic levels. Intercellular communication occurs via a direct contact between cells as well as by secretory contact-independent mechanisms. However, there are few existing methods that allow quantitative resolution of contact-dependent and independent cellular processes in a rapid, precisely controlled, and dynamic format. This study utilizes a high-throughput microfluidic droplet array platform to analyze cell-cell interaction and effector functions at single cell level...
September 2016: Biomicrofluidics
https://www.readbyqxmd.com/read/27504298/non-secretory-myeloma-diagnosed-on-renal-biopsy-as-cast-nephropathy
#3
Sumit Grover, Pavneet Kaur Selhi, Neena Sood, Jasvinder Singh Sandhu, Harpreet Kaur
Multiple myeloma is a disorder of plasma cells which can involve kidneys in the form of cast nephropathy. Neoplastic plasma cells produce either complete immunoglobulins or fragments of immunoglobulins leading to a monoclonal spike in the serum and/or Bence Jones proteinuria. Very few patients present as non-secretory myeloma when no immunoglobulins (M spike) are produced or only light chains are secreted which can only be detected in urine. Acute renal failure due to cast nephropathy can rarely be the first presentation of multiple myeloma...
June 2016: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/27221891/international-scoring-system-in-symptomatic-multiple-myeloma-experience-from-a-tertiary-care-center
#4
Sadia Sultan, Syed Mohammed Irfan, Saira Parveen, Ufaq Taufiq
BACKGROUND: Symptomatic multiple myeloma (MM) is an acquired B-cell malignant proliferation of anti- body secreting plasma cells, characterized by end organ damage due to monoclonal immunoglobulin secretion. The aim of this study wa to determine the stage stratification according to an international scoring system in adult Pakistani MM patients at presentation. MATERIALS AND METHODS: This single centre retrospective study extendedfrom January 2012 to December 2015...
2016: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/27104188/plasma-cell-leukemia-in-north-india-retrospective-analysis-of-a-distinct-clinicohematological-entity-from-a-tertiary-care-center-and-review-of-literature
#5
Karthik Bommannan, Man Updesh Singh Sachdeva, Pankaj Malhotra, Narender Kumar, Prashant Sharma, Shano Naseem, Jasmina Ahluwalia, Reena Das, Neelam Varma, Gaurav Prakash, Alka Khadwal, Radhika Srinivasan, Subhash Varma
BACKGROUND: Plasma cell leukemia (PCL) is a rare and aggressive plasma cell neoplasm. In PCL, clonal plasma cells comprise ≥20% of the peripheral blood (PB) leukocytes and/or the absolute clonal PB plasma cell count is ≥2×10(9)/L. Primary PCL (PPCL) originates de novo, whereas, secondary PCL (SPCL) evolves from pre-existing multiple myeloma. METHODS: Clinicohematological features, immunophenotypic profile, and survival of PCL patients were analyzed retrospectively...
March 2016: Blood Research
https://www.readbyqxmd.com/read/26875957/pleural-effusion-in-multiple-myeloma
#6
Zhuo Wang, Guoguang Xia, Ling Lan, Fayong Liu, Yanxun Wang, Baoyue Liu, Yi Ding, Li Dai, Yunjian Zhang
OBJECTIVE: Pleural effusion is rarely observed in patients with multiple myeloma (MM). Myeloma cell infiltration or invasion to the pleura is very rare. This study aimed to investigate the clinical characteristics of pleural effusion in patients with MM. METHODS: We retrospectively reviewed the medical records of patients diagnosed with pleural effusion, MM, and pleural effusion with MM between 2004 and 2014 at Beijing Jishuitan Hospital. The present study included patients with pleural effusion who underwent cytological, bacteriological, biochemical and other testing...
2016: Internal Medicine
https://www.readbyqxmd.com/read/26621901/spontaneous-sternal-fracture-due-to-multiple-myeloma-requiring-extensive-surgical-repair
#7
Ellen M Bp Reuling, Tijs S C Jakma, Johannes Marco Schnater, Peter E Westerweel
Spontaneous sternal fracture is a well-known complication of multiple myeloma due to osteolytic bone lesions. The possibility of a multiple myeloma should be thoroughly investigated in patients presenting with a spontaneous sternal fracture. This work up should go beyond protein electrophoresis alone as a monoclonal paraprotein is not always present. In some cases, the myeloma plasma cell clone produces only the free light chain (κ or λ) or may even be non-secretory. The underlying plasma cell dyscrasia is treated with chemotherapy and, if needed, local radiotherapy...
2015: BMJ Case Reports
https://www.readbyqxmd.com/read/26528383/non-secretory-multiple-myeloma-with-extensive-extramedullary-plasmacytoma-a-diagnostic-dilemma
#8
Soo Fin Low, Nor Hanani Mohd Tap, Thean Yean Kew, Chai Soon Ngiu, Radhika Sridharan
Multiple myeloma (MM) is characterized by progressive proliferation of malignant plasma cells, usually initiating in the bone marrow. MM can affect any organ; a total of 7 - 18% of patients with MM demonstrate extramedullary involvement at diagnosis. Non-secretory multiple myeloma (NSMM) is a rare variant that accounts for 1 - 5% of all cases of multiple myeloma. The disease is characterized by the absence of monoclonal gammopathy in serum and urine electrophoresis. Our case report highlights the diagnostic challenge of a case of NSMM with extensive extramedullary involvement in a young female patient who initially presented with right shoulder pain and bilateral breasts lumps...
July 2015: Iranian Journal of Radiology: a Quarterly Journal Published By the Iranian Radiological Society
https://www.readbyqxmd.com/read/26464727/bone-formation-following-lenalidomide-dexamethasone-combination-therapy-in-cases-of-multiple-myeloma-refractory-to-high-dose-chemotherapy-with-bortezomib-and-autologous-peripheral-blood-stem-cell-transplantation-report-of-a-case-and-review-of-the-literature
#9
REVIEW
Yasunobu Sekiguchi, Kunimoto Ichikawa, Mutsumi Wakabayashi, Keiji Sugimoto, Shigeki Tomita, Hiroshi Izumi, Noriko Nakamura, Tomohiro Sawada, Yasunori Ohta, Norio Komatsu, Masaaki Noguchi
A 41-year-old man presented with the chief complaint of right hip pain that had persisted for 6 months. F18-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) imaging showed FDG accumulation in the right pubic bone. A bone biopsy specimen from the site revealed findings suggestive of a plasma cell tumor. Bone marrow examination and serum and urine immunofixation tests showed no abnormalities. Based on these findings, the patient was diagnosed as having non-secretory multiple myeloma...
2015: International Journal of Clinical and Experimental Pathology
https://www.readbyqxmd.com/read/26108343/high-expression-of-endoplasmic-reticulum-chaperone-grp94-is-a-novel-molecular-hallmark-of-malignant-plasma-cells-in-multiple-myeloma
#10
Saurabh Chhabra, Sandeep Jain, Caroline Wallace, Feng Hong, Bei Liu
BACKGROUND: Multiple myeloma (MM) is a hematologic malignancy that is characterized by the proliferation of abnormal bone marrow plasma cells (BMPC) and overproduction of immunoglobulin or light chains with evidence of end-organ damage such as bone damage, anemia, hypercalcemia, and renal dysfunction. The pathogenesis of MM is closely linked to dysregulated unfolded protein response (UPR) in the endoplasmic reticulum (ER). Constitutive activation of UPR in mice, as demonstrated by transgenic expression of a master UPR transcription factor XBP1s (a UPR-specific splice variant of X-box binding protein 1), causes myeloma...
2015: Journal of Hematology & Oncology
https://www.readbyqxmd.com/read/26003102/a-rare-variant-of-multiple-myeloma-non-secretory-myeloma-with-diffuse-osteolytic-lesions
#11
S Sultan, S M Irfan
Non-secretory myeloma is a very rare entity of plasma cell dyscrasia. It is delineated as symptomatic myeloma without detectable monoclonal immunoglobulin peak on serum or urine electrophoresis with normal immunoquantification. Due to the inability to detect monoclonality often it is difficult to ascertain an early and accurate diagnosis. Misdiagnosing results to undue delay in therapeutic intervention. Consequently extensive imaging studies, serum free light chains detection and morphological confirmation are mandatory...
May 2015: Gulf Journal of Oncology
https://www.readbyqxmd.com/read/25690913/clinical-course-and-prognosis-of-non-secretory-multiple-myeloma
#12
Sagar S Chawla, Shaji K Kumar, Angela Dispenzieri, Alexandra J Greenberg, Dirk R Larson, Robert A Kyle, Martha Q Lacy, Morie A Gertz, S Vincent Rajkumar
OBJECTIVE: To determine the prognosis of patients with non-secretory myeloma. Methods: We studied 124 patients diagnosed with multiple myeloma who had no monoclonal protein detected on serum and urine immunofixation at diagnosis and on all subsequent follow up testing (non-secretory myeloma). The overall survival (OS) of patients with non-secretory myeloma was compared with 7075 patients with typical myeloma seen during the same time period in whom a monoclonal protein was detected at the time of diagnosis...
February 16, 2015: European Journal of Haematology
https://www.readbyqxmd.com/read/25382589/clinical-course-and-prognosis-of-non-secretory-multiple-myeloma
#13
Sagar S Chawla, Shaji K Kumar, Angela Dispenzieri, Alexandra J Greenberg, Dirk R Larson, Robert A Kyle, Martha Q Lacy, Morie A Gertz, S Vincent Rajkumar
OBJECTIVE: To determine the prognosis of patients with non-secretory myeloma. METHODS: We studied 124 patients diagnosed with multiple myeloma who had no monoclonal protein detected on serum and urine immunofixation at diagnosis and on all subsequent follow-up testing (non-secretory myeloma). The overall survival (OS) of patients with non-secretory myeloma was compared with 6953 patients with typical myeloma seen during the same time period in whom a monoclonal protein was detected at the time of diagnosis...
July 2015: European Journal of Haematology
https://www.readbyqxmd.com/read/25218739/%C3%A2-%C3%A2-f-fdg-pet-ct-a-review-of-diagnostic-and-prognostic-features-in-multiple-myeloma-and-related-disorders
#14
REVIEW
Franco Dammacco, Giuseppe Rubini, Cristina Ferrari, Angelo Vacca, Vito Racanelli
Conventional radiographic skeletal survey has been for many years the gold standard to detect the occurrence of osteolytic lesions in patients with multiple myeloma (MM). However, the introduction of more sensitive imaging procedures has resulted in an updated anatomic and functional Durie and Salmon "plus" staging system and has remarkably changed the diagnostic and prognostic approach to this tumor. It is now established that (18)fluorine-fluorodeoxyglucose ((18)F-FDG) positron-emission tomography (PET) combined with low-dose computed tomography (CT), shortly designated PET/CT, exhibits a higher screening and diagnostic sensitivity and specificity over the skeleton X-ray...
February 2015: Clinical and Experimental Medicine
https://www.readbyqxmd.com/read/24489083/serum-free-light-chain-assay-clinical-utility-and-limitations
#15
REVIEW
Malini V Bhole, Ross Sadler, Karthik Ramasamy
In the last decade, the introduction of the serum-free light-chain (sFLC) assay has been an important advance in the diagnosis and management of plasma cell dyscrasias, particularly monoclonal light-chain diseases. The immunoassay was developed to detect free light chains in serum by using anti-FLC antibodies which specifically recognised epitopes on light chains that were 'hidden' in intact immunoglobulins. Since its introduction in 2001, there have been several publications in the English language literature discussing the clinical utility as well as analytical limitations of the sFLC assay...
September 2014: Annals of Clinical Biochemistry
https://www.readbyqxmd.com/read/24326882/-multiple-myeloma-with-significant-multifocal-osteolysis-in-a-dog-without-a-detectible-gammopathy
#16
F Souchon, A Koch, A Sohns
Description of a variant of multiple myeloma in a dog lacking the gammopathy normally associated with this type of neoplasm. A Border Collie mongrel was presented with symptoms of progressive hind-leg weakness, lethargy and tiredness, which had started to appear 6 weeks previously. Radiographic examination showed small osteolytic areas in the spinal column, but also diffuse small areas of increased opacity as well as evidence of decreased bone density in the pelvis and of both femoral necks. Moderate regenerative anaemia, hypogammopathy and hypercalcaemia were diagnosed...
2013: Tierärztliche Praxis. Ausgabe K, Kleintiere/Heimtiere
https://www.readbyqxmd.com/read/24282993/non-secretory-myeloma-a-clinician-s-guide
#17
REVIEW
Sagar Lonial, Jonathan L Kaufman
The treatment of patients with multiple myeloma has dramatically changed over the past 10 years due to an improved understanding of plasma cell biology and the development of new targets. The subset of these patients with non-secretory myeloma-a group of patients who do not secrete immunoglobulin or its component parts into either the blood or urine-has been challenging to treat and to assess for disease response. Newer methods of assessment for plasma cell disorders, such as the widely used serum free light chain assay, have reduced the number of patients with truly non-secretory myeloma to less than 3% of all newly diagnosed myeloma patients...
September 2013: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/24133785/oligosecretory-biclonal-multiple-myeloma
#18
Nebu Koshy, Menchu G Ong, Mary Lowery Nordberg, Francesco Turturro, James D Cotelingam
Among the plasma cell dyscrasias, non-secretory myeloma is one of the rarest. This diagnosis is based on the absence of monoclonal proteins in the serum and urine. When serum free light chains are trace and the kappa: lambda ratio normal, clonality may however be established by PCR. We present a case of an oligosecretory myeloma confirmed by PCR, which would have hitherto been classified as non-secretory.
July 2013: Journal of the Louisiana State Medical Society: Official Organ of the Louisiana State Medical Society
https://www.readbyqxmd.com/read/24069311/combined-inhibition-of-p97-and-the-proteasome-causes-lethal-disruption-of-the-secretory-apparatus-in-multiple-myeloma-cells
#19
Holger W Auner, Anne Marie Moody, Theresa H Ward, Marianne Kraus, Enrico Milan, Philippa May, Aristeidis Chaidos, Christoph Driessen, Simone Cenci, Francesco Dazzi, Amin Rahemtulla, Jane F Apperley, Anastasios Karadimitris, Niall Dillon
Inhibition of the proteasome is a widely used strategy for treating multiple myeloma that takes advantage of the heavy secretory load that multiple myeloma cells (MMCs) have to deal with. Resistance of MMCs to proteasome inhibition has been linked to incomplete disruption of proteasomal endoplasmic-reticulum (ER)-associated degradation (ERAD) and activation of non-proteasomal protein degradation pathways. The ATPase p97 (VCP/Cdc48) has key roles in mediating both ERAD and non-proteasomal protein degradation and can be targeted pharmacologically by small molecule inhibition...
2013: PloS One
https://www.readbyqxmd.com/read/24025541/the-emergence-of-non-secretory-multiple-myeloma-during-the-non-cytotoxic-treatment-of-essential-thrombocythemia-a-case-report
#20
Danijela Leković, Mirjana Gotić, Olivera Mitrović, Milica Radojković, Jelena Bila, Marija Dencic-Fekete, Nada Kraguljac-Kurtović, Maja Peruničić-Jovanović, Vladan Cokić
INTRODUCTION: The emergence of multiple myeloma as a second malignancy in patients with essential thrombocythemia is extremely rare. Several cases have been published so far, pointing out the impact of a cytotoxic effect during treatment of essential thrombocythemia on the development of multiple myeloma. CASE PRESENTATION: We report the case of a 52-year-old Caucasian man who presented to our hospital because of leukocytosis, a slightly decreased hemoglobin level and thrombocytosis...
2013: Journal of Medical Case Reports
keyword
keyword
62748
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"